Qualitative analysis of patient-centered decision attributes associated with initiating hepatitis C treatment

Jessica L Zuchowski, Alison B Hamilton, Jeffrey M Pyne, Jack A Clark, Aanand D Naik, Donna L Smith, Fasiha Kanwal, Jessica L Zuchowski, Alison B Hamilton, Jeffrey M Pyne, Jack A Clark, Aanand D Naik, Donna L Smith, Fasiha Kanwal

Abstract

Background: In this era of a constantly changing landscape of antiviral treatment options for chronic viral hepatitis C (CHC), shared clinical decision-making addresses the need to engage patients in complex treatment decisions. However, little is known about the decision attributes that CHC patients consider when making treatment decisions. We identify key patient-centered decision attributes, and explore relationships among these attributes, to help inform the development of a future CHC shared decision-making aid.

Methods: Semi-structured qualitative interviews with CHC patients at four Veterans Health Administration (VHA) hospitals, in three comparison groups: contemplating CHC treatment at the time of data collection (Group 1), recently declined CHC treatment (Group 2), or recently started CHC treatment (Group 3). Participant descriptions of decision attributes were analyzed for the entire sample as well as by patient group and by gender.

Results: Twenty-nine Veteran patients participated (21 males, eight females): 12 were contemplating treatment, nine had recently declined treatment, and eight had recently started treatment. Patients on average described eight (range 5-13) decision attributes. The attributes most frequently reported overall were: physical side effects (83%); treatment efficacy (79%), new treatment drugs in development (55%); psychological side effects (55%); and condition of the liver (52%), with some variation based on group and gender. Personal life circumstance attributes (such as availability of family support and the burden of financial responsibilities) influencing treatment decisions were also noted by all participants. Multiple decision attributes were interrelated in highly complex ways.

Conclusions: Participants considered numerous attributes in their CHC treatment decisions. A better understanding of these attributes that influence patient decision-making is crucial in order to inform patient-centered clinical approaches to care (such as shared decision-making augmented with relevant decision-making aids) that respond to patients' needs, preferences, and circumstances.

Figures

Fig. 1
Fig. 1
Selected Relationships Between Decision Attributes

References

    1. Alter MJ, Kruszon-Moran D, Nainan OV, McQuillan GM, Gao F, Moyer LA, et al. The prevalence of hepatitis C virus infection in the United States, 1988 through 1994. N Engl J Med. 1999;341(8):556–562. doi: 10.1056/NEJM199908193410802.
    1. Armstrong GL, Wasley A, Simard EP, McQuillan GM, Kuhnert WL, Alter MJ. The Prevalence of Hepatitis C Virus Infection in the United States,1999 through 2002. Ann Intern Med. 2006;144:705–714. doi: 10.7326/0003-4819-144-10-200605160-00004.
    1. Ponynard T, McHutchison J, Manns M, Trepo C, Lindsay K, Goodman Z, et al. Impact of pegylated interferon alfa-2b and ribavirin on liver fibrosis in patients with chronic hepatitis C. Gastroenterology. 2002;122(5):1303–1313. doi: 10.1053/gast.2002.33023.
    1. Shiratori Y, Ito Y, Yokosuka O, Imazeki F, Nakata R, Tanaka N, et al. Antiviral therapy for cirrhotic hepatitis C: association with reduced hepatocellular carcinoma development and improved survival. Ann Intern Med. 2005;142(2):105–114. doi: 10.7326/0003-4819-142-2-200501180-00009.
    1. Spiegel BM, Younossi ZM, Hays RD, Revicki D, Robbins S, Kanwal F. Impact of hepatitis C on health related quality of life: a systematic review and quantitative assessment. Hepatology. 2005;41(4):790–800. doi: 10.1002/hep.20659.
    1. Berenguer J, Alvarez-Pellicer J, Martin PM, López-Aldeguer J, Von-Wichmann MA, Quereda C, et al. Sustained virological response to interferon plus ribavirin reduces liver-related complications and mortality in patients coinfected with human immunodeficiency virus and hepatitis C virus. Hepatology. 2009;50(2):407–413. doi: 10.1002/hep.23020.
    1. Butt AA, Wang X, Moore CG. Effect of hepatitis C virus and its treatment on survival. Hepatology. 2009;50(2):387–392. doi: 10.1002/hep.23000.
    1. John-Baptiste AA, Tomlinson G, Hsu PC, Krajden M, Heathcote EJ, Laporte A, et al. Sustained responders have better quality of life and productivity compared with treatment failures long after antiviral therapy for hepatitis C. Am J Gastroenterol. 2009;104(10):2439–2448. doi: 10.1038/ajg.2009.346.
    1. Singal AG, Volk ML, Jensen D. Di Bisceglie AM. A sustained viral response is associated with reduced liver-related morbidity and mortality in patients with hepatitis C virus. Clin Gastroenterol Hepatol: Schoenfeld PS; 2009.
    1. Veldt BJ, Heathcote EJ, Wedemeyer H, Reichen J, Hofmann WP, Zeuzem S, et al. Sustained virologic response and clinical outcomes in patients with chronic hepatitis C and advanced fibrosis. Ann Intern Med. 2007;147(10):677–684. doi: 10.7326/0003-4819-147-10-200711200-00003.
    1. Lawitz E, Mangia A, Wyles D, Rodriguez-Torres M, Hassanein T, Gordon SC, et al. Sofosbuvir for previously untreated chronic hepatitis C infection. N Engl J Med. 2013;368:1878–1887. doi: 10.1056/NEJMoa1214853.
    1. Zeuzem S, Berg T, Gane E, Ferenci P, Foster GR, Fried MW, et al. Simeprevir increases rate of sustained virologic response among treatment-experienced patients with HCV genotype-1 infection: a phase IIb trial. Gastroenterology. 2014;146:430–441. doi: 10.1053/j.gastro.2013.10.058.
    1. Jacobson IM, Ghalib RH, Rodriguez-Torres M, et al. SVR results of a once-daily regimen of simeprevir (TMC435) plus sofosbuvir (GS-7977) with or without ribavirin in cirrhotic and non-cirrhotic HCV genotype 1 treatment-naive and prior null responder patients: the COSMOS study. Hepatology. 2013;58:1379A.
    1. Sussman NL, Remien CH, Kanwal F. The end of hepatitis C. Clin Gastroenterol Hepatol. 2014;12(4):533–6. doi: 10.1016/j.cgh.2014.01.025.
    1. Ilyas JA, Vierling JM. An overview of emerging therapies for the treatment of chronic hepatitis C. Med Clin North Am. 2014;98(1):17–38. doi: 10.1016/j.mcna.2013.10.011.
    1. Innes H, Goldberg D, Dusheiko G, Hayes P, Mills PR, Dillon JF, Aspinall E, Barclay ST, Hutchinson SJ. Patient-important benefits of clearing the hepatitis C virus through treatment: a simulation model. J Hepatol. 2014;60(6):1118–26. doi: 10.1016/j.jhep.2014.01.020.
    1. Fraenkel L, McGraw S, Wongcharatrawee S, Garcia-Tsao G. What do patients consider when making decisions about treatment for hepatitis C? Am J Med. 2005;118(12):1387–91. doi: 10.1016/j.amjmed.2005.05.029.
    1. Khokhar OS, Lewis JH. Reasons Why Patients Infected with Chronic Hepatitis C Virus Choose to Defer Treatment: Do They Alter Their Decision with Time? Dig Dis Sci. 2007;52(5):1168–1176. doi: 10.1007/s10620-006-9579-1.
    1. Tovo CV, de Mattos AA, de Almeida PR. Chronic hepatitis C genotype 1 virus: who should wait for treatment? World J Gastroenterol. 2014;20(11):2867–75. doi: 10.3748/wjg.v20.i11.2867.
    1. Cotler SJ, Patil R, McNutt RA, Speroff T, Banaad-Omiotek G, Ganger DR, Rosenblate H, Kaur S, Cotler S, Jensen DM. Patients’ values for health states associated with hepatitis C and physicians’ estimates of those values. Am J Gastroenterol. 2001;96(9):2730–6. doi: 10.1111/j.1572-0241.2001.04132.x.
    1. Abraham NS, Naik AD, Street RL. Shared Decision Making in GI Clinic to Improve Patient Adherence. Clin Gastroenterol Hepatol. 2012;10(8):825–827. doi: 10.1016/j.cgh.2012.06.001.
    1. Naik AD, Kallen MA, Walder A, Street RL., Jr Improving hypertension control in diabetes mellitus: the effects of collaborative and proactive health communication. Circulation. 2008;117(11):1361–1368. doi: 10.1161/CIRCULATIONAHA.107.724005.
    1. Naik AD. On the Road to Patient Centeredness. JAMA. 2013;173(3):218–219.
    1. Elwyn G, Frosch D, Thomson R, Joseph-Williams N, Lloyd A, Kinnersley P, Cording E, et al. Shared decision making: a model for clinical practice. J Gen Intern Med. 2012;27(10):1361–1367. doi: 10.1007/s11606-012-2077-6.
    1. Légaré F, Stacey D, Pouliot S, Gauvin FP, Desroches S, Kryworuchko J, et al. Interprofessionalism and shared decision-making in primary care: a stepwise approach towards a new model. J Interprof Care. 2011;25:18–25. doi: 10.3109/13561820.2010.490502.
    1. Elwyn G, O'Connor A, Stacey D, Volk R, Edwards A, Coulter A, et al. Developing a quality criteria framework for patient decision aids: online international Delphi consensus process. BMJ. 2006;333(7565):417. doi: 10.1136/.
    1. Rosedale MT, Strauss SM. How persons with chronic hepatitis C in residential substance abuse treatment programs think about depression and interferon therapy. J Am Psychiatr Nurses Assoc. 2010;16(6):350–6. doi: 10.1177/1078390310392784.
    1. Treloar C, Hopwood M. “Look, I’m fit, I’m positive and I’ll be all right, thank you very much”: coping with hepatitis C treatment and unrealistic optimism. Psychol Health Med. 2008;13(3):360–6. doi: 10.1080/13548500701477532.
    1. Fraenkel L, McGraw S, Wongcharatrawee S, Garcia-Tsao G. Patients’ experiences related to anti-viral treatment for hepatitis C. Patient Educ Couns. 2006;62(1):148–55. doi: 10.1016/j.pec.2005.06.019.
    1. Bova C, Ogawa LF, Sullivan-Bolyai S. Hepatitis C treatment experiences and decision making among patients living with HIV infection. J Assoc Nurses AIDS Care. 2010;21(1):63–74. doi: 10.1016/j.jana.2009.07.009.
    1. Ogawa LM, Bova C. HCV treatment decision-making substance use experiences and hepatitis C treatment decision-making among HIV/HCV Coinfected Adults. Subst Use Misuse. 2009;44(7):915–33. doi: 10.1080/10826080802486897.
    1. Osilla KC, Ryan G, Bhatti L, Goetz M, Witt M, Wagner G. Decision attributes that influence an HIV coinfected patient’s decision to start hepatitis C treatment. AIDS Patient Care STDS. 2009;23(12):993–999. doi: 10.1089/apc.2009.0153.
    1. Hughes KA. Comparing pretesting methods: Cognitive interviews, respondent debriefing, and behavior coding. U.S. Bureau of the Census Statistical Research Division Research Report Series: Survey Methodology. 2004:1–20.
    1. Averill JB. Matrix analysis as a complementary analytic strategy in qualitative inquiry. Qual Health Res. 2002;12(6):855–66. doi: 10.1177/104973230201200611.
    1. Glaser BG. The constant comparative method of qualitative analysis. Soc Probl. 1965;12:436–445. doi: 10.2307/798843.
    1. Glaser BG, Strauss AL. The Discovery of Grounded Theory: Strategies for Qualitative Research. New Brunswick, NJ: Aldine Publishing Company; 1967.
    1. Boeije H. A purposeful approach to the constant comparative method in the analysis of qualitative interviews. Qual Quant. 2002;35:391–409. doi: 10.1023/A:1020909529486.
    1. Hinojosa‐Lindsey M, Arney J, Heberlig S, Kramer JR, Street RL, Jr, El‐Serag HB, Naik AD. Patients’ intuitive judgments about surveillance endoscopy in Barrett’s esophagus: a review and application to models of decision‐making. Dis Esophagus. 2013;26(7):682–689.
    1. Reyna VF. A theory of medical decision making and health: fuzzy trace theory. Med Decis Mak. 2008.
    1. Street RL, Jr, Makoul G, Arora NK, Epstein RM. How does communication heal? Pathways linking clinician-patient communication to health outcomes. Patient Educ Couns. 2009;74:295–301. doi: 10.1016/j.pec.2008.11.015.
    1. Naik AD, McCullough LB. Health Intuitions Inform Patient-Centered Care. Am J Bioeth. 2014;14(6):1–3. doi: 10.1080/15265161.2014.915650.
    1. Fraenkel L, Peters E, Charpentier P, Olsen B, Errante L, Schoen RT, Reyna V. Decision tool to improve the quality of care in rheumatoid arthritis. Arthritis Care Res (Hoboken) 2012;64(7):977–985.
    1. Naik AD, El-Serag HB. Decision Aids for Shared Decision-Making in Barrett’s Esophagus Surveillance. Clin Gastroenterol Hepatol. 2015;13(1):91. doi: 10.1016/j.cgh.2014.05.004.
    1. Ho SB, Groessl E, Dollarhide A, Robinson S, Kravetz D, Dieperink E. Management of Chronic Hepatitis C in Veterans: The Potential of Integrated Care Models. Am J Gastroenterol. 2008;103:1810–1823. doi: 10.1111/j.1572-0241.2008.01877.x.

Source: PubMed

赞助者和合作者

医疗条件

药物干预

3
订阅